Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 151

1.

Unique pattern of neutrophil migration and function during tumor progression.

Patel S, Fu S, Mastio J, Dominguez GA, Purohit A, Kossenkov A, Lin C, Alicea-Torres K, Sehgal M, Nefedova Y, Zhou J, Languino LR, Clendenin C, Vonderheide RH, Mulligan C, Nam B, Hockstein N, Masters G, Guarino M, Schug ZT, Altieri DC, Gabrilovich DI.

Nat Immunol. 2018 Nov;19(11):1236-1247. doi: 10.1038/s41590-018-0229-5. Epub 2018 Oct 15.

PMID:
30323345
2.

A phase I trial of pembrolizumab with hypofractionated radiotherapy in patients with metastatic solid tumours.

Maity A, Mick R, Huang AC, George SM, Farwell MD, Lukens JN, Berman AT, Mitchell TC, Bauml J, Schuchter LM, O'Hara M, Lin LL, Demichele A, Christodouleas JP, Haas NB, Patsch DM, Hahn SM, Minn AJ, Wherry EJ, Vonderheide RH.

Br J Cancer. 2018 Nov;119(10):1200-1207. doi: 10.1038/s41416-018-0281-9. Epub 2018 Oct 15.

PMID:
30318516
3.

Extended CCR5 Blockade for Graft-versus-Host Disease Prophylaxis Improves Outcomes of Reduced-Intensity Unrelated Donor Hematopoietic Cell Transplantation: A Phase II Clinical Trial.

Reshef R, Ganetsky A, Acosta EP, Blauser R, Crisalli L, McGraw J, Frey NV, Hexner EO, Hoxie JA, Loren AW, Luger SM, Mangan J, Stadtmauer EA, Mick R, Vonderheide RH, Porter DL.

Biol Blood Marrow Transplant. 2018 Oct 10. pii: S1083-8791(18)30601-3. doi: 10.1016/j.bbmt.2018.09.034. [Epub ahead of print]

PMID:
30315941
4.

Long-term outcomes of a phase I study of agonist CD40 antibody and CTLA-4 blockade in patients with metastatic melanoma.

Bajor DL, Mick R, Riese MJ, Huang AC, Sullivan B, Richman LP, Torigian DA, George SM, Stelekati E, Chen F, Melenhorst JJ, Lacey SF, Xu X, Wherry EJ, Gangadhar TC, Amaravadi RK, Schuchter LM, Vonderheide RH.

Oncoimmunology. 2018 Aug 20;7(10):e1468956. doi: 10.1080/2162402X.2018.1468956. eCollection 2018.

5.

Rucaparib Monotherapy in Patients With Pancreatic Cancer and a Known Deleterious BRCA Mutation.

Shroff RT, Hendifar A, McWilliams RR, Geva R, Epelbaum R, Rolfe L, Goble S, Lin KK, Biankin AV, Giordano H, Vonderheide RH, Domchek SM.

JCO Precis Oncol. 2018;2018. doi: 10.1200/PO.17.00316. Epub 2018 May 16.

6.

Tumor Cell-Intrinsic Factors Underlie Heterogeneity of Immune Cell Infiltration and Response to Immunotherapy.

Li J, Byrne KT, Yan F, Yamazoe T, Chen Z, Baslan T, Richman LP, Lin JH, Sun YH, Rech AJ, Balli D, Hay CA, Sela Y, Merrell AJ, Liudahl SM, Gordon N, Norgard RJ, Yuan S, Yu S, Chao T, Ye S, Eisinger-Mathason TSK, Faryabi RB, Tobias JW, Lowe SW, Coussens LM, Wherry EJ, Vonderheide RH, Stanger BZ.

Immunity. 2018 Jul 17;49(1):178-193.e7. doi: 10.1016/j.immuni.2018.06.006. Epub 2018 Jun 26.

PMID:
29958801
7.

Hif1α Deletion Limits Tissue Regeneration via Aberrant B Cell Accumulation in Experimental Pancreatitis.

Lee KE, Spata M, Maduka R, Vonderheide RH, Simon MC.

Cell Rep. 2018 Jun 19;23(12):3457-3464. doi: 10.1016/j.celrep.2018.05.071.

8.

Immunotherapy and Prevention of Pancreatic Cancer.

Morrison AH, Byrne KT, Vonderheide RH.

Trends Cancer. 2018 Jun;4(6):418-428. doi: 10.1016/j.trecan.2018.04.001. Epub 2018 Apr 30. Review.

PMID:
29860986
9.

Radiotherapy and CD40 Activation Separately Augment Immunity to Checkpoint Blockade in Cancer.

Rech AJ, Dada H, Kotzin JJ, Henao-Mejia J, Minn AJ, Twyman-Saint Victor C, Vonderheide RH.

Cancer Res. 2018 Aug 1;78(15):4282-4291. doi: 10.1158/0008-5472.CAN-17-3821. Epub 2018 May 29.

PMID:
29844122
10.

Understanding the tumor immune microenvironment (TIME) for effective therapy.

Binnewies M, Roberts EW, Kersten K, Chan V, Fearon DF, Merad M, Coussens LM, Gabrilovich DI, Ostrand-Rosenberg S, Hedrick CC, Vonderheide RH, Pittet MJ, Jain RK, Zou W, Howcroft TK, Woodhouse EC, Weinberg RA, Krummel MF.

Nat Med. 2018 May;24(5):541-550. doi: 10.1038/s41591-018-0014-x. Epub 2018 Apr 23. Review.

11.

The Immune Revolution: A Case for Priming, Not Checkpoint.

Vonderheide RH.

Cancer Cell. 2018 Apr 9;33(4):563-569. doi: 10.1016/j.ccell.2018.03.008. Review.

PMID:
29634944
12.

Tumor Immunity and Survival as a Function of Alternative Neopeptides in Human Cancer.

Rech AJ, Balli D, Mantero A, Ishwaran H, Nathanson KL, Stanger BZ, Vonderheide RH.

Cancer Immunol Res. 2018 Jan 16. doi: 10.1158/2326-6066.CIR-17-0559. [Epub ahead of print]

PMID:
29339376
13.

Cancer-Associated Fibroblasts Neutralize the Anti-tumor Effect of CSF1 Receptor Blockade by Inducing PMN-MDSC Infiltration of Tumors.

Kumar V, Donthireddy L, Marvel D, Condamine T, Wang F, Lavilla-Alonso S, Hashimoto A, Vonteddu P, Behera R, Goins MA, Mulligan C, Nam B, Hockstein N, Denstman F, Shakamuri S, Speicher DW, Weeraratna AT, Chao T, Vonderheide RH, Languino LR, Ordentlich P, Liu Q, Xu X, Lo A, Puré E, Zhang C, Loboda A, Sepulveda MA, Snyder LA, Gabrilovich DI.

Cancer Cell. 2017 Nov 13;32(5):654-668.e5. doi: 10.1016/j.ccell.2017.10.005.

14.

Safety and Efficacy of Intratumoral Injections of Chimeric Antigen Receptor (CAR) T Cells in Metastatic Breast Cancer.

Tchou J, Zhao Y, Levine BL, Zhang PJ, Davis MM, Melenhorst JJ, Kulikovskaya I, Brennan AL, Liu X, Lacey SF, Posey AD Jr, Williams AD, So A, Conejo-Garcia JR, Plesa G, Young RM, McGettigan S, Campbell J, Pierce RH, Matro JM, DeMichele AM, Clark AS, Cooper LJ, Schuchter LM, Vonderheide RH, June CH.

Cancer Immunol Res. 2017 Dec;5(12):1152-1161. doi: 10.1158/2326-6066.CIR-17-0189. Epub 2017 Nov 6.

15.

Pharmacodynamic Monitoring Predicts Outcomes of CCR5 Blockade as Graft-versus-Host Disease Prophylaxis.

Huffman AP, Richman LP, Crisalli L, Ganetsky A, Porter DL, Vonderheide RH, Reshef R.

Biol Blood Marrow Transplant. 2018 Mar;24(3):594-599. doi: 10.1016/j.bbmt.2017.10.028. Epub 2017 Oct 20.

16.

Immunotherapy for Breast Cancer: What Are We Missing?

Vonderheide RH, Domchek SM, Clark AS.

Clin Cancer Res. 2017 Jun 1;23(11):2640-2646. doi: 10.1158/1078-0432.CCR-16-2569.

17.

T-cell invigoration to tumour burden ratio associated with anti-PD-1 response.

Huang AC, Postow MA, Orlowski RJ, Mick R, Bengsch B, Manne S, Xu W, Harmon S, Giles JR, Wenz B, Adamow M, Kuk D, Panageas KS, Carrera C, Wong P, Quagliarello F, Wubbenhorst B, D'Andrea K, Pauken KE, Herati RS, Staupe RP, Schenkel JM, McGettigan S, Kothari S, George SM, Vonderheide RH, Amaravadi RK, Karakousis GC, Schuchter LM, Xu X, Nathanson KL, Wolchok JD, Gangadhar TC, Wherry EJ.

Nature. 2017 May 4;545(7652):60-65. doi: 10.1038/nature22079. Epub 2017 Apr 10.

18.

T-Cell Transfer Therapy Targeting Mutant KRAS.

Rech AJ, Vonderheide RH.

N Engl J Med. 2017 Feb 16;376(7):e11. No abstract available.

PMID:
28207208
19.

Class I-restricted T-cell responses to a polymorphic peptide in a gene therapy clinical trial for α-1-antitrypsin deficiency.

Calcedo R, Somanathan S, Qin Q, Betts MR, Rech AJ, Vonderheide RH, Mueller C, Flotte TR, Wilson JM.

Proc Natl Acad Sci U S A. 2017 Feb 14;114(7):1655-1659. doi: 10.1073/pnas.1617726114. Epub 2017 Jan 30.

20.

Clinical and immunologic impact of CCR5 blockade in graft-versus-host disease prophylaxis.

Moy RH, Huffman AP, Richman LP, Crisalli L, Wang XK, Hoxie JA, Mick R, Emerson SG, Zhang Y, Vonderheide RH, Porter DL, Reshef R.

Blood. 2017 Feb 16;129(7):906-916. doi: 10.1182/blood-2016-08-735076. Epub 2017 Jan 5.

21.

Immune Cytolytic Activity Stratifies Molecular Subsets of Human Pancreatic Cancer.

Balli D, Rech AJ, Stanger BZ, Vonderheide RH.

Clin Cancer Res. 2017 Jun 15;23(12):3129-3138. doi: 10.1158/1078-0432.CCR-16-2128. Epub 2016 Dec 22.

22.

Tumor Interferon Signaling Regulates a Multigenic Resistance Program to Immune Checkpoint Blockade.

Benci JL, Xu B, Qiu Y, Wu TJ, Dada H, Twyman-Saint Victor C, Cucolo L, Lee DSM, Pauken KE, Huang AC, Gangadhar TC, Amaravadi RK, Schuchter LM, Feldman MD, Ishwaran H, Vonderheide RH, Maity A, Wherry EJ, Minn AJ.

Cell. 2016 Dec 1;167(6):1540-1554.e12. doi: 10.1016/j.cell.2016.11.022.

23.

CXCR2-Dependent Accumulation of Tumor-Associated Neutrophils Regulates T-cell Immunity in Pancreatic Ductal Adenocarcinoma.

Chao T, Furth EE, Vonderheide RH.

Cancer Immunol Res. 2016 Nov;4(11):968-982. Epub 2016 Oct 13.

24.

Lack of immunoediting in murine pancreatic cancer reversed with neoantigen.

Evans RA, Diamond MS, Rech AJ, Chao T, Richardson MW, Lin JH, Bajor DL, Byrne KT, Stanger BZ, Riley JL, Markosyan N, Winograd R, Vonderheide RH.

JCI Insight. 2016 Sep 8;1(14). pii: 88328. doi: 10.1172/jci.insight.88328.

25.

Metastatic progression is associated with dynamic changes in the local microenvironment.

Aiello NM, Bajor DL, Norgard RJ, Sahmoud A, Bhagwat N, Pham MN, Cornish TC, Iacobuzio-Donahue CA, Vonderheide RH, Stanger BZ.

Nat Commun. 2016 Sep 15;7:12819. doi: 10.1038/ncomms12819.

26.

Recommendations for myeloid-derived suppressor cell nomenclature and characterization standards.

Bronte V, Brandau S, Chen SH, Colombo MP, Frey AB, Greten TF, Mandruzzato S, Murray PJ, Ochoa A, Ostrand-Rosenberg S, Rodriguez PC, Sica A, Umansky V, Vonderheide RH, Gabrilovich DI.

Nat Commun. 2016 Jul 6;7:12150. doi: 10.1038/ncomms12150. Review.

27.

CD40 Stimulation Obviates Innate Sensors and Drives T Cell Immunity in Cancer.

Byrne KT, Vonderheide RH.

Cell Rep. 2016 Jun 21;15(12):2719-32. doi: 10.1016/j.celrep.2016.05.058. Epub 2016 Jun 9.

28.

CSF-1R-Dependent Lethal Hepatotoxicity When Agonistic CD40 Antibody Is Given before but Not after Chemotherapy.

Byrne KT, Leisenring NH, Bajor DL, Vonderheide RH.

J Immunol. 2016 Jul 1;197(1):179-87. doi: 10.4049/jimmunol.1600146. Epub 2016 May 23.

29.

De-Risking Immunotherapy: Report of a Consensus Workshop of the Cancer Immunotherapy Consortium of the Cancer Research Institute.

Mellman I, Hubbard-Lucey VM, Tontonoz MJ, Kalos MD, Chen DS, Allison JP, Drake CG, Levitsky H, Lonberg N, van der Burg SH, Fearon DT, Wherry EJ, Lowy I, Vonderheide RH, Hwu P.

Cancer Immunol Res. 2016 Apr;4(4):279-88. doi: 10.1158/2326-6066.CIR-16-0045. Review.

30.

Infusion of CD3/CD28 costimulated umbilical cord blood T cells at the time of single umbilical cord blood transplantation may enhance engraftment.

Hexner EO, Luger SM, Reshef R, Jeschke GR, Mangan JK, Frey NV, Frank DM, Richman LP, Vonderheide RH, Aqui NA, Rosenbach M, Zhang Y, Chew A, Loren AW, Stadtmauer EA, Levine BL, June CH, Emerson SG, Porter DL.

Am J Hematol. 2016 May;91(5):453-60. doi: 10.1002/ajh.24303. Epub 2016 Apr 4.

31.

Hif1a Deletion Reveals Pro-Neoplastic Function of B Cells in Pancreatic Neoplasia.

Lee KE, Spata M, Bayne LJ, Buza EL, Durham AC, Allman D, Vonderheide RH, Simon MC.

Cancer Discov. 2016 Mar;6(3):256-69. doi: 10.1158/2159-8290.CD-15-0822. Epub 2015 Dec 29.

32.

CD47 blockade as another immune checkpoint therapy for cancer.

Vonderheide RH.

Nat Med. 2015 Oct;21(10):1122-3. doi: 10.1038/nm.3965. No abstract available.

PMID:
26444633
33.

High Graft CD8 Cell Dose Predicts Improved Survival and Enables Better Donor Selection in Allogeneic Stem-Cell Transplantation With Reduced-Intensity Conditioning.

Reshef R, Huffman AP, Gao A, Luskin MR, Frey NV, Gill SI, Hexner EO, Kambayashi T, Loren AW, Luger SM, Mangan JK, Nasta SD, Richman LP, Sell M, Stadtmauer EA, Vonderheide RH, Mick R, Porter DL.

J Clin Oncol. 2015 Jul 20;33(21):2392-8. doi: 10.1200/JCO.2014.60.1203. Epub 2015 Jun 8.

34.

The Impact of EBV Status on Characteristics and Outcomes of Posttransplantation Lymphoproliferative Disorder.

Luskin MR, Heil DS, Tan KS, Choi S, Stadtmauer EA, Schuster SJ, Porter DL, Vonderheide RH, Bagg A, Heitjan DF, Tsai DE, Reshef R.

Am J Transplant. 2015 Oct;15(10):2665-73. doi: 10.1111/ajt.13324. Epub 2015 May 18.

35.

Tumor-Promoting Desmoplasia Is Disrupted by Depleting FAP-Expressing Stromal Cells.

Lo A, Wang LS, Scholler J, Monslow J, Avery D, Newick K, O'Brien S, Evans RA, Bajor DJ, Clendenin C, Durham AC, Buza EL, Vonderheide RH, June CH, Albelda SM, Puré E.

Cancer Res. 2015 Jul 15;75(14):2800-2810. doi: 10.1158/0008-5472.CAN-14-3041. Epub 2015 May 15.

36.

Special Conference on Tumor Immunology and Immunotherapy: A New Chapter.

Byrne KT, Vonderheide RH, Jaffee EM, Armstrong TD.

Cancer Immunol Res. 2015 Jun;3(6):590-597. doi: 10.1158/2326-6066.CIR-15-0106. Epub 2015 May 12.

37.

Exclusion of T Cells From Pancreatic Carcinomas in Mice Is Regulated by Ly6C(low) F4/80(+) Extratumoral Macrophages.

Beatty GL, Winograd R, Evans RA, Long KB, Luque SL, Lee JW, Clendenin C, Gladney WL, Knoblock DM, Guirnalda PD, Vonderheide RH.

Gastroenterology. 2015 Jul;149(1):201-10. doi: 10.1053/j.gastro.2015.04.010. Epub 2015 Apr 14.

38.

Lack of a significant pharmacokinetic interaction between maraviroc and tacrolimus in allogeneic HSCT recipients.

Ganetsky A, Miano TA, Hughes ME, Vonderheide RH, Porter DL, Reshef R.

J Antimicrob Chemother. 2015 Jul;70(7):2078-83. doi: 10.1093/jac/dkv082. Epub 2015 Apr 16.

39.

Awakening the immune system with radiation: Optimal dose and fractionation.

Gandhi SJ, Minn AJ, Vonderheide RH, Wherry EJ, Hahn SM, Maity A.

Cancer Lett. 2015 Nov 28;368(2):185-90. doi: 10.1016/j.canlet.2015.03.024. Epub 2015 Mar 20. Review.

PMID:
25799953
40.

NKG2D expression by CD8+ T cells contributes to GVHD and GVT effects in a murine model of allogeneic HSCT.

Karimi MA, Bryson JL, Richman LP, Fesnak AD, Leichner TM, Satake A, Vonderheide RH, Raulet DH, Reshef R, Kambayashi T.

Blood. 2015 Jun 4;125(23):3655-63. doi: 10.1182/blood-2015-02-629006. Epub 2015 Mar 18.

41.

Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer.

Twyman-Saint Victor C, Rech AJ, Maity A, Rengan R, Pauken KE, Stelekati E, Benci JL, Xu B, Dada H, Odorizzi PM, Herati RS, Mansfield KD, Patsch D, Amaravadi RK, Schuchter LM, Ishwaran H, Mick R, Pryma DA, Xu X, Feldman MD, Gangadhar TC, Hahn SM, Wherry EJ, Vonderheide RH, Minn AJ.

Nature. 2015 Apr 16;520(7547):373-7. doi: 10.1038/nature14292. Epub 2015 Mar 9.

42.

Induction of T-cell Immunity Overcomes Complete Resistance to PD-1 and CTLA-4 Blockade and Improves Survival in Pancreatic Carcinoma.

Winograd R, Byrne KT, Evans RA, Odorizzi PM, Meyer AR, Bajor DL, Clendenin C, Stanger BZ, Furth EE, Wherry EJ, Vonderheide RH.

Cancer Immunol Res. 2015 Apr;3(4):399-411. doi: 10.1158/2326-6066.CIR-14-0215. Epub 2015 Feb 12.

43.

Immune activation and a 9-year ongoing complete remission following CD40 antibody therapy and metastasectomy in a patient with metastatic melanoma.

Bajor DL, Xu X, Torigian DA, Mick R, Garcia LR, Richman LP, Desmarais C, Nathanson KL, Schuchter LM, Kalos M, Vonderheide RH.

Cancer Immunol Res. 2014 Nov;2(11):1051-8. doi: 10.1158/2326-6066.CIR-14-0154. Epub 2014 Sep 24.

44.

Anti-human CD40 monoclonal antibody therapy is potent without FcR crosslinking.

Richman LP, Vonderheide RH.

Oncoimmunology. 2014 Apr 29;3:e28610. eCollection 2014.

45.

Tumor-promoting inflammatory networks in pancreatic neoplasia: another reason to loathe Kras.

Vonderheide RH.

Cancer Cell. 2014 May 12;25(5):553-4. doi: 10.1016/j.ccr.2014.04.020.

46.

CD4+ T lymphocyte ablation prevents pancreatic carcinogenesis in mice.

Zhang Y, Yan W, Mathew E, Bednar F, Wan S, Collins MA, Evans RA, Welling TH, Vonderheide RH, di Magliano MP.

Cancer Immunol Res. 2014 May;2(5):423-35. doi: 10.1158/2326-6066.CIR-14-0016-T. Epub 2014 Feb 11.

47.

ER stress regulates myeloid-derived suppressor cell fate through TRAIL-R-mediated apoptosis.

Condamine T, Kumar V, Ramachandran IR, Youn JI, Celis E, Finnberg N, El-Deiry WS, Winograd R, Vonderheide RH, English NR, Knight SC, Yagita H, McCaffrey JC, Antonia S, Hockstein N, Witt R, Masters G, Bauer T, Gabrilovich DI.

J Clin Invest. 2014 Jun;124(6):2626-39. doi: 10.1172/JCI74056. Epub 2014 May 1.

48.

Mitigating the toxic effects of anticancer immunotherapy.

Gangadhar TC, Vonderheide RH.

Nat Rev Clin Oncol. 2014 Feb;11(2):91-9. doi: 10.1038/nrclinonc.2013.245. Epub 2014 Jan 21. Review.

PMID:
24445516
49.

Role of crosslinking for agonistic CD40 monoclonal antibodies as immune therapy of cancer.

Richman LP, Vonderheide RH.

Cancer Immunol Res. 2014 Jan;2(1):19-26. doi: 10.1158/2326-6066.CIR-13-0152.

50.

Engineering T cells for cancer: our synthetic future.

Vonderheide RH, June CH.

Immunol Rev. 2014 Jan;257(1):7-13. doi: 10.1111/imr.12143. No abstract available.

Supplemental Content

Loading ...
Support Center